Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 5Venous Thromboembolism 4Venous Thrombosis 3Pulmonary Embolism 3Thrombosis 1Prostatic Neoplasms 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Embolism 1Cushing Syndrome 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1

Interventions

Acupuncture Therapy 10Gabapentin 7Venlafaxine Hydrochloride 5Tamoxifen 3Isoflavones 3Estrogens, Conjugated (USP) 3Bupivacaine 3liposomal amphotericin B 2fezolinetant 2black cohosh root extract 2Soybean Proteins 2Sodium Chloride 2Moxifloxacin 2Magnesium Oxide 2Hypnosis 2Control Groups 2Citalopram 2Caspofungin 2zopiclone 1oxybutynin 1bazedoxifene 1Zolpidem 1Vitamin B 6 1Vancomycin 1Therapeutics 1Testosterone 1Tazobactam 1Tablets 1Sugars 1Solifenacin Succinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hot Flashes × Dabigatran × Clear all
NCT05471817 2022-11-22

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Bayer

Phase 1 Completed
20 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡